Clinical and Experimental Medicine

, Volume 17, Issue 4, pp 441–449 | Cite as

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis

  • Shichao Tong
  • Ji Liu
  • Changqing Zhang
Original Article


Rheumatoid arthritis (RA) is a chronic disease affecting daily life of numerous patients, and uncontrolled proliferation of synovial fibroblasts plays vital role during the pathology of RA. Platelet-rich plasma (PRP), widely used in tissue regeneration and pain management, is rarely studied in RA. This study aims to investigate the effect of PRP on synovial fibroblasts during RA. Rheumatoid fibroblast-like synoviocyte MH7A cells were stimulated by lipopolysaccharide (LPS) to simulate RA conditions and treated with PRP, after that the concentration of inflammatory factors interleukin (IL) 1β, tumor necrosis factor alpha (TNFα) and IL6 in the supernatant of culture medium was quantified by ELISA. MTT assay, flow cytometry and tube formation assay were performed to assess changes in cell viability, apoptosis and effect on angiogenesis in vitro, respectively. Besides, the expression levels of main factors in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signal pathway were examined. Results showed that PRP markedly inhibited the production of IL1β, TNFα and IL6 (P < 0.05) that was stimulated by LPS. LPS promoted MH7A cell viability, inhibited apoptosis and accelerated angiogenesis in vitro, while PRP could markedly relieve these effects (P < 0.05). The mRNA and protein levels of AKT1, PI3K (p58) and nuclear factor κ beta were elevated by LPS and then suppressed by PRP (P < 0.01). This study uncovered the potential of PRP in inhibiting inflammation, repressing synovial fibroblasts and regulating the PI3K/AKT signaling, providing basic proof for future application of PRP in managing RA. Further investigation is necessary to reveal detailed mechanism of PRP.


Rheumatoid arthritis Platelet-rich plasma Inflammatory factor Angiogenesis Phosphoinositide 3-kinase 



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.


  1. 1.
    Costenbader KH, Chang SC, Laden F, Puett R, Karlson EW. Geographic variation in rheumatoid arthritis incidence among women in the United States. Archives of Internal Medicine. 2008;168(15):1664–70.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–108.CrossRefPubMedGoogle Scholar
  3. 3.
    Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Annals of the Rheumatic Diseases. 2011;70(3):508–11. doi: 10.1136/ard.2009.120899.CrossRefPubMedGoogle Scholar
  4. 4.
    Kato K, Segami N, Fukuda H, Minato H. Rheumatoid nodule in the lower lip of a patient with rheumatoid arthritis: a novel case report and review of literature. Journal of Oral and Maxillofacial Surgery. 2014;72(8):1532.e1–5.CrossRefGoogle Scholar
  5. 5.
    Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis and Rheumatism. 2010;62(6):1583–91.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212(2):377–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. New England Journal of Medicine. 1997;337(3):141–7.CrossRefPubMedGoogle Scholar
  8. 8.
    McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011;365(23):2205–19.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhai Y, Wu B, Li J, Yao XY, Zhu P, Chen ZN. CD147 promotes IKK/IκB/NF-κB pathway to resist TNF-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Mol Med (Berl). 2016;94(1):71–82.CrossRefGoogle Scholar
  10. 10.
    Chen Y, Dawes PT, Mattey DL. Polymorphism in the vascular endothelial growth factor A (VEGFA) gene is associated with serum VEGF-A level and disease activity in rheumatoid arthritis: differential effect of cigarette smoking. Cytokine. 2012;58(3):390–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. American Journal of Sports Medicine. 2009;37(11):2259–72. doi: 10.1177/0363546509349921.CrossRefPubMedGoogle Scholar
  12. 12.
    Kaux JF, Crielaard JM. Platelet-rich plasma application in the management of chronic tendinopathies. Acta Orthopaedica Belgica. 2013;79(1):10–5.PubMedGoogle Scholar
  13. 13.
    Zhu X, Zhang C, Huang GT, Cheung GS, Dissanayaka WL, Zhu W. Transplantation of dental pulp stem cells and platelet-rich plasma for pulp regeneration. J Endod. 2012;38(12):1604–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Knezevic NN, Candido KD, Desai R, Kaye AD. Is platelet-rich plasma a future therapy in pain management? Medical Clinics of North America. 2016;100(1):199–217.CrossRefPubMedGoogle Scholar
  15. 15.
    Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intra-articular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surgery, Sports Traumatology, Arthroscopy. 2011;19(4):528–35.CrossRefPubMedGoogle Scholar
  16. 16.
    Jang SJ, Kim JD, Cha SS. Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis. European Journal of Orthopaedic Surgery & Traumatology. 2013;23(5):573–80.CrossRefGoogle Scholar
  17. 17.
    Kon E, Filardo G, Di MB, Marcacci M. PRP for the treatment of cartilage pathology. Open Orthopaed J. 2013;7(7):120–8.CrossRefGoogle Scholar
  18. 18.
    Osterman C, McCarthy MB, Cote MP, et al. Platelet-rich plasma increases anti-inflammatory markers in a human coculture model for osteoarthritis. American Journal of Sports Medicine. 2015;43(6):1474–84. doi: 10.1177/0363546515570463.CrossRefPubMedGoogle Scholar
  19. 19.
    Kang J, Yuan W, Chang Z, Sun H, Yu X. Study of proliferation of chondrocytes co-cultured with platelet rich gel. J Reg Anat Operat Surg. 2015;24(4):387–9 (in Chinese).Google Scholar
  20. 20.
    Mohammadi E, Vatanpour H, Shirazi FH. Immunomodulatory effects of bee venom in human synovial fibroblast cell line. Iran J Pharm Res. 2015;14(1):313–20.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Zhao G, Zhu Y, Eno CO, et al. Activation of the proapoptotic BCL-2 protein BAX by a small molecule induces tumor cell apoptosis. Molecular and Cellular Biology. 2014;34(7):1198–207. doi: 10.1128/mcb.00996-13.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death and Differentiation. 2014;21(2):206–15. doi: 10.1038/cdd.2013.153.CrossRefPubMedGoogle Scholar
  23. 23.
    Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451(7181):1008–12. doi: 10.1038/nature06613.CrossRefPubMedGoogle Scholar
  24. 24.
    Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cellular Immunology. 1994;157(1):291–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Andreassen SM, Berg LC, Nielsen SS, Kristensen AT, Jacobsen S. mRNA expression of genes involved in inflammation and haemostasis in equine fibroblast-like synoviocytes following exposure to lipopolysaccharide, fibrinogen and thrombin. BMC Vet Res. 2015;11:141.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Seong AR, Yoo JY, Choi K, et al. Delphinidin, a specific inhibitor of histone acetyltransferase, suppresses inflammatory signaling via prevention of NF-κB acetylation in fibroblast-like synoviocyte MH7A cells. Biochem Biophys Res Commun. 2011;410(3):581–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nature Reviews Rheumatology. 2013;9(12):721–30.CrossRefPubMedGoogle Scholar
  29. 29.
    Ji H, Huo X, Zhang H, Wang Y, Shi X, Huo L. Platelet-rich plasma with sodium hyaluronate in repair of rabbit knee osteoarthritis. Chin J Tissue Eng Res. 2015;19(38):6133–9.Google Scholar
  30. 30.
    Amable PR, Carias RBV, Teixeira MVT, da Cruz Pacheco Í, do Amaral RJFC, Granjeiro JM, Borojevic R. Platelet-rich plasma preparation for regenerative medicine optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(67):13.Google Scholar
  31. 31.
    Jin XN, Yan EZ, Wang HM, et al. Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. Acta Pharmacologica Sinica. 2016;37(5):674–86.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Rezende MUD, Silva RBBD, Bassit ACF, Tatsui NH, Sadigursky D, Neto RB. Effect of platelet-rich plasma on impact-induced chondrocyte apoptosis. Acta Ortop Bras. 2011;19(2):102–5.CrossRefGoogle Scholar
  33. 33.
    Drengk A, Zapf A, Stürmer EK, Stürmer KM, Frosch KH. Influence of platelet-rich plasma on chondrogenic differentiation and proliferation of chondrocytes and mesenchymal stem cells. Cells Tissues Organs. 2009;189(5):317–26.CrossRefPubMedGoogle Scholar
  34. 34.
    Kakudo N, Minakata T, Mitsui T, Kushida S, Notodihardjo FZ, Kusumoto K. Proliferation-promoting effect of platelet-rich plasma on human adipose-derived stem cells and human dermal fibroblasts. Plastic and Reconstructive Surgery. 2008;122(5):1352–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. Journal of Biological Chemistry. 2000;275(1):444–50.CrossRefPubMedGoogle Scholar
  36. 36.
    Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Investig. 1995;94(6):2489–92.CrossRefGoogle Scholar
  37. 37.
    Lippross S, Moeller B, Haas H, et al. Intraarticular injection of platelet-rich plasma reduces inflammation in a pig model of rheumatoid arthritis of the knee joint. Arthritis and Rheumatism. 2011;63(11):3344–53. doi: 10.1002/art.30547.CrossRefPubMedGoogle Scholar
  38. 38.
    Braun HJ, Kim HJ, Chu CR, Dragoo JL. The effect of platelet-rich plasma formulations and blood products on human synoviocytes: implications for intra-articular injury and therapy. American Journal of Sports Medicine. 2014;42(5):1204–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Lyras DN, Kazakos K, Verettas D, et al. The influence of platelet-rich plasma on angiogenesis during the early phase of tendon healing. Foot and Ankle International. 2009;30(11):1101–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Browning SR, Weiser AM, Woolf N, et al. Platelet-rich plasma increases matrix metalloproteinases in cultures of human synovial fibroblasts. Journal of Bone and Joint Surgery. American Volume. 2012;94(23):e1721–7. doi: 10.2106/JBJS.K.01501.CrossRefGoogle Scholar
  41. 41.
    Wang J, Zhang W, Zou H, et al. 10-Hydroxy-2-decenoic acid inhibiting the proliferation of fibroblast-like synoviocytes by PI3K-AKT pathway. International Immunopharmacology. 2015;28(1):97–104.CrossRefPubMedGoogle Scholar
  42. 42.
    Hsieh CJ, Hall K, Ha T, Li C, Krishnaswamy G, Chi DS. Baicalein inhibits IL-1β- and TNF-α-induced inflammatory cytokine production from human mast cells via regulation of the NF-κB pathway. Clin Mol Allergy. 2007;5:5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Orthopaedics, Shanghai Sixth People’s HospitalShanghai Jiaotong UniversityShanghaiChina
  2. 2.Department of Orthopaedics, Shanghai Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations